Oncotarget

Research Perspectives:

Rapamycin in aging and disease: maximizing efficacy while minimizing side effects

Simon C. Johnson and Matt Kaeberlein _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:44876-44878. https://doi.org/10.18632/oncotarget.10381

Metrics: PDF 2248 views  |   HTML 2409 views  |   ?  


Abstract

Simon C. Johnson1 and Matt Kaeberlein2

1 Department of Genetics, Albert Einstein Medical College, New York, NY, USA

2 Department of Pathology, University of Washington, Seattle, WA, USA

Correspondence to:

Matt Kaeberlein, email:

Keywords: mTOR, target of rapamycin, healthspan, mitochondria, mitochondria disease

Received: April 22, 2016 Accepted: June 16, 2016 Published: July 01, 2016

Abstract

Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10381